Nowadays, it has been clearly established that the EGFR gene mutational status comprises a powerful predictor of the tumour responses to EGFR-TKI treatments (Lynch et al. 2004; Janne et al. 2005; Cappuzzo et al. 2005, Takano et al. 2005; Hirsch et al. 2006; van Zandwijk et al. 2007; Mitsudomi et al. 2010), in consequence being widely used to select patients likely to respond to the medication. Here, EGFR is linked to neoplasm.